Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Oct 2, 2025 · Filed Oct 3, 2025
Vertex Pharmaceuticals's and Chief Legal Officer sold $281K of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$280,522
Shares × reported transaction price
59 days after results of Aug 4, 2025, 32 days before results of Nov 3, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $408.85 on Oct 2, 2025, 12% above its 52-week low and 21% below its high, after a 4% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $516.74 (Nov 8, 2024), 28% of the way up, from 250 adjusted closes. 30 trading days earlier: $394.36 on Aug 20, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.1% | -1.3% | +2.4% |
| 30 days | +3.5% | +0.9% | +2.6% |
| 90 days | +11.4% | +2.4% | +9.0% |
| 180 days | +7.8% | -1.9% | +9.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Routine share withholding; mechanical by default.
